Spectrum Pharmaceuticals (SPPI +6%) trades up after submitting an investigation new drug...

|About: Spectrum Pharmaceuticals, Inc. (SPPI)|By:, SA News Editor

Spectrum Pharmaceuticals (SPPI +6%) trades up after submitting an investigation new drug application to the FDA for SPI-014, a lanthanum-based nanoparticle phosphate binding agent that can potentially treat hyperphosphatemia in patients with end-stage renal disease. The company plans to start Phase I studies as soon as possible after the FDA review.